CINECA IRIS Institutional Research Information System

CIRCOSTA, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.901
EU - Europa 1.387
AS - Asia 480
AF - Africa 28
SA - Sud America 17
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.848
IT - Italia 429
CN - Cina 240
IE - Irlanda 195
SE - Svezia 182
DE - Germania 137
AT - Austria 70
FR - Francia 67
GB - Regno Unito 67
UA - Ucraina 64
CA - Canada 51
IN - India 45
VN - Vietnam 41
FI - Finlandia 37
PL - Polonia 31
KR - Corea 30
HK - Hong Kong 28
BE - Belgio 21
SG - Singapore 21
JP - Giappone 19
IR - Iran 17
NL - Olanda 16
SN - Senegal 15
BR - Brasile 11
RU - Federazione Russa 10
CH - Svizzera 7
GR - Grecia 7
ID - Indonesia 7
AU - Australia 6
NG - Nigeria 6
PK - Pakistan 6
TR - Turchia 6
CZ - Repubblica Ceca 5
DK - Danimarca 5
HR - Croazia 5
IQ - Iraq 5
PT - Portogallo 5
TW - Taiwan 5
ES - Italia 4
SK - Slovacchia (Repubblica Slovacca) 4
UZ - Uzbekistan 4
BG - Bulgaria 3
HU - Ungheria 3
RO - Romania 3
RS - Serbia 3
AR - Argentina 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
MA - Marocco 2
MK - Macedonia 2
NO - Norvegia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BY - Bielorussia 1
BZ - Belize 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MC - Monaco 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 3.821
Salva come PNG Salva come JPEG
Città #
Chandler 375
Dublin 192
Beijing 113
Torino 105
Nyköping 97
Ann Arbor 80
Ashburn 75
Jacksonville 75
Vienna 70
Fairfield 63
Turin 61
Houston 56
Medford 53
Woodbridge 53
Princeton 44
Redwood City 42
Dearborn 41
Wilmington 39
Fremont 37
Milan 26
Warsaw 25
Dong Ket 22
Seattle 22
Villeurbanne 21
Brussels 20
Cambridge 20
Shanghai 19
Guangzhou 18
New York 18
Washington 18
Québec 17
Boardman 14
Nanjing 14
Pisa 14
Menlo Park 13
Rome 13
Ottawa 12
Boston 11
Bologna 9
Los Angeles 8
Tai Wan 8
Viterbo 8
West Jordan 8
Amsterdam 7
Delhi 7
Jinan 7
Riverside 7
Toronto 7
Abuja 6
Chengdu 6
Chennai 6
Epsom 6
Hangzhou 6
Hebei 6
Kunming 6
San Diego 6
Bari 5
Cassano Magnago 5
Falls Church 5
Hefei 5
Jakarta 5
Lisbon 5
Novara 5
Nürnberg 5
Reston 5
San Jose 5
San Mateo 5
Uppsala 5
Valdagno 5
Bratislava 4
Central 4
Central District 4
Chongqing 4
Florence 4
Gunzenhausen 4
Hamburg 4
Liverpool 4
Luni 4
Munich 4
Nichelino 4
Sesto Fiorentino 4
Belgrade 3
Bloomsbury 3
Bordeaux 3
Capriate San Gervasio 3
Copenhagen 3
Des Moines 3
Duncan 3
Fazal 3
Leinì 3
London 3
Malappuram 3
Manchester 3
Montreal 3
Naples 3
Norwalk 3
Otemae 3
Padova 3
Rivoli 3
Saint-frédéric 3
Totale 2.302
Salva come PNG Salva come JPEG
Nome #
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 243
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 239
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 223
miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions 165
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 154
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
The molecular and functional characterization of clonally expanded CD8 + TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA) 143
Clonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndrome 114
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 105
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia 98
Nanocarriers as magic bullets in the treatment of leukemia 97
TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells 94
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 91
High Basal γH2AX Levels Sustain Self-Renewal of Mouse Embryonic and Induced Pluripotent Stem Cells. 89
High basal γH2AX levels sustain self-renewal of mouse embryonic and induced pluripotent stem cells 87
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 81
Functional phenotype of peripheral lymphocytes in Churg Strauss syndrome 79
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 76
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and Leukemic CD5+ B lymphocytes 73
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 71
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 69
Differential effects on CLL cell survival exerted by different microenvironmental elements. 67
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 66
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity 65
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 61
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 60
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 59
Molecular and Functional Analysis of Peripheral Lymphocytes in Churg Strauss Syndrome Reveals Several Monoclonal Expansions of CD8+Cells with a Th1/Proinflammatory Profile 58
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 58
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 57
Signalling through the sTCR/CD3 complex can regulate RAG1/RAG2 protein expression and TCR revision in mature human T lymphocytes 53
Signaling through the sTCR/CD3 complex can regulate RAG1/RAG2 protein expression and TCR revision in mature T lymphocytes 50
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 45
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 43
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 42
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 41
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 39
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 38
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 32
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 32
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 29
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 29
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 27
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 27
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 25
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 25
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 16
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 16
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 14
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role. 11
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 10
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role 4
Totale 3.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.418
article - articoli 0
book - libri 0
conference - conferenze 6.512
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019148 0 0 0 0 0 0 0 0 0 66 46 36
2019/2020473 36 23 11 40 23 66 81 34 32 53 49 25
2020/2021505 40 43 39 69 38 14 32 17 57 39 50 67
2021/2022653 22 15 41 49 33 36 43 31 20 71 183 109
2022/20231.202 101 142 39 122 95 284 82 69 106 45 71 46
2023/2024429 66 75 46 35 14 72 40 13 8 60 0 0
Totale 3.949